Biotech Turns To Private Investors
This article was originally published in Start Up
Executive Summary
As the public market for biotech issues has dried up, it's not surprising that public biotechs would rely more heavily on institutional investors for financing. Notable, however, is that so far this year, publicly traded biotechs have actually raised more cash privately than they have in follow-on public offerings.
You may also be interested in...
Corporate Investments In Biotech
Public biotechs now rely as much as ever on institutional funding, as public equity markets remain chilly. But, for a step-up in valuation, biotechs can only turn to corporate investors, who might be persuaded to pay a strategic premium.
Corporate Investments In Biotech
Public biotechs now rely as much as ever on institutional funding, as public equity markets remain chilly. But, for a step-up in valuation, biotechs can only turn to corporate investors, who might be persuaded to pay a strategic premium.
Latest Boom in Biotech Financing
Public markets have soured considerably on new biotech issues since the record-breaking offerings of 2000. The amount of private money raised has steadily grown above that of public offerings for the past three months.